Oxazolidinone-quinolone hybrid antibacterial for the parenteral treatment of prophylaxis of bacterial diseases
AssigneeMorphochem Aktiengesellschaft Fur Kombinatorische Chemie
InventorsThomas KAPSNER, Axel DALHOFF, Thomas GRAMATTE
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of oxazolidinone-quinolone hybrids for the parenteral (especially intravenous) treatment or prophylaxis of bacterial diseases. The present invention relates moreover to improved methods of administering oxazolidinone-quinolone hybrid antibacterials.
Claims21
1-32. (canceled)
A method for treating a bacterial infection caused by Clostridium difficile, comprising administering to a patient in need thereof a compound, which is 7-(4-{4-[(5S)-5-(acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenoxymethyl}-4-phosphonooxy-piperidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid:
- or a pharmacologically acceptable salt thereof.
A method for treating an intestinal disease caused by Clostridium difficile, comprising administering to a patient in need thereof a compound, which is 7-(4-{4-[(5S)-5-(acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenoxymethyl}-4-phosphonooxy-piperidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid:
- or a pharmacologically acceptable salt thereof, wherein the compound, or a pharmacologically acceptable salt thereof, is administered daily at an infusion rate of 0.5 mg/(kg body weight×h) over a period of 12 h per day for a period of 10 days.
Dependencies are inferred from the claim text.